Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sangzhi alkaloids
- Development stage
- Unknown
- Lead developer
- Beijing Wehand-Bio Pharmaceutical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Sangzhi alkaloids is a botanical drug derived from the twigs of *Morus alba* L. (Mulberry twigs), which was approved by the National Medical Products Administration (NMPA) of China in 2020 for the treatment of type 2 diabetes mellitus. It is a refined extract containing a group of polyhydroxy alkaloids, with 1-deoxynojirimycin (DNJ), fagomine, and 1,4-dideoxy-1,4-imino-D-arabinitol (DAB) as the primary active components. The drug acts as an alpha-glucosidase inhibitor, delaying the digestion and absorption of carbohydrates in the small intestine, thereby reducing postprandial blood glucose levels. Beyond its primary indication, it is being investigated for its potential to improve metabolic disorders in perimenopausal women, including glucose and lipid metabolism abnormalities, both as a monotherapy and in combination with menopausal hormone therapy.
- Brand names
- Sangzhi Zongshengwujian
- Other names
- Mulberry twig alkaloidsTotal alkaloids of Ramulus MoriRamulus Mori alkaloidsSangzhi Zongshengwujian tablets
02
Targets
Sucrase-Isomaltase
Beyond the preview
Go deeper on sangzhi alkaloids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sangzhi alkaloids.